Rallybio (RLYB) Accounts Payables (2020 - 2026)
Rallybio (RLYB) posted Accounts Payables of $940000.0 for Q1 2026, up 646.03% sequentially from $126000.0 in Q4 2025, and up 135.0% YoY from $400000.0 in Q1 2025.
Rallybio (RLYB) Accounts Payables (2020 - 2026) Analysis & Trends
Rallybio has reported Accounts Payables for 7 years, with the latest figure at $940000.0 in Q1 2026.
- Quarterly Accounts Payables rose 135.0% year-over-year to $940000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $940000.0 (up 135.0% YoY) and the FY2025 annual result came in at $126000.0, down 54.68% from the prior year.
- Accounts Payables improved to $940000.0 in Q1 2026 per RLYB's latest filing, from $126000.0 in the prior quarter.
- Over five years, Accounts Payables peaked at $1.2 million in Q2 2024 and troughed at $119000.0 in Q2 2025.
- A 5-year average of $643882.4 and a median of $633000.0 in 2022 frame the typical range for Accounts Payables.
- The sharpest annual moves came in 2025 and 2026: Accounts Payables sank 90.23% in 2025, then surged 135.0% in 2026.
- Over 5 years, Accounts Payables stood at $1.1 million in 2022, then declined by 12.39% to $976000.0 in 2023, then sank by 71.52% to $278000.0 in 2024, then slumped by 54.68% to $126000.0 in 2025, then soared by 646.03% to $940000.0 in 2026.
- According to Business Quant data, Accounts Payables over the past three periods registered $940000.0, $126000.0, and $269000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Rallybio | 94.61 Mn | 94.61 Mn | - | 833,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 833,000.00 |
| Mar 31, 2026 | 940,000.00 |
| Dec 31, 2025 | 126,000.00 |
| Sep 30, 2025 | 269,000.00 |
| Jun 30, 2025 | 119,000.00 |
| Mar 31, 2025 | 400,000.00 |
| Dec 31, 2024 | 278,000.00 |
| Sep 30, 2024 | 583,000.00 |
| Jun 30, 2024 | 1.22 Mn |
| Mar 31, 2024 | 470,000.00 |
| Dec 31, 2023 | 976,000.00 |
| Sep 30, 2023 | 464,000.00 |
| Jun 30, 2023 | 689,000.00 |
| Mar 31, 2023 | 782,000.00 |
| Dec 31, 2022 | 1.11 Mn |
| Sep 30, 2022 | 828,000.00 |
| Jun 30, 2022 | 633,000.00 |
| Mar 31, 2022 | 1.06 Mn |
| Dec 31, 2021 | 603,000.00 |
| Sep 30, 2021 | 2.60 Mn |